Main Menu

Our Work

Grifols' proposed acquisition of Talecris

For more information, download the case study

Provided analysis on behalf of Grifols in connection with its acquisition of Talecris, both companies involved in the manufacture and sale of plasma-derived therapies used to treat a range of medical conditions. Evaluated possible coordinated effects concerns and assessed the merger specificity of claimed efficiencies in analysis presented to the FTC. Subsequent to a second request, FTC approved the transaction after Grifols agreed to a consent decree with provisions to facilitate entry.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.